MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia

Experimental Hematology

Volumn 36, Issue 4, 2008, Pages 433-442

  Ho, Maria M ^a   Hogge, Donna E ^a   Ling, Victor ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN 1; VALSPODAR; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CD34 SELECTION; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 40649100954     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.11.014     Document Type: Article

References (49)

1. Mitus A., and Rosenthal D. The adult leukemias. In: Lenhard R.E.J. (Ed). American Cancer Society Textbook of Clinical Oncology (1995), American Cancer Society, Atlanta, Ga 486-500
2. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455 (1976) 152-162
3. Cole S.P., Bhardwaj G., Gerlach J.H., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
4. Doyle L.A., Yang W., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95 (1998) 15665-15670
5. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
6. van der Kolk D.M., de Vries E.G., Muller M., and Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 43 (2002) 685-701
7. Marie J.P., Zittoun R., and Sikic B.I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78 (1991) 586-592
8. Pirker R., Wallner J., Geissler K., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83 (1991) 708-712
9. Borg A.G., Burgess R., Green L.M., Scheper R.J., and Yin J.A. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 103 (1998) 1083-1091
10. Del Poeta G., Venditti A., Stasi R., et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 23 (1999) 451-465
11. Wuchter C., Leonid K., Ruppert V., et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85 (2000) 711-721
12. Zochbauer S., Gsur A., Brunner R., Kyrle P.A., Lechner K., and Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8 (1994) 974-977
13. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
14. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100 (2002) 1224-1232
15. Damiani D., Tiribelli M., Calistri E., et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91 (2006) 825-828
16. Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., and Marie J.P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94 (1999) 1046-1056
17. Legrand O., Simonin G., Perrot J.Y., Zittoun R., and Marie J.P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91 (1998) 4480-4488
18. Steinbach D., Sell W., Voigt A., Hermann J., Zintl F., and Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16 (2002) 1443-1447
19. van der Kolk D.M., de Vries E.G., van Putten W.J., et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6 (2000) 3205-3214
20. Abbott B.L., Colapietro A.M., Barnes Y., Marini F., Andreeff M., and Sorrentino B.P. Low levels of ABCG2 expression in adult AML blast samples. Blood 100 (2002) 4594-4601
21. Filipits M., Suchomel R.W., Zochbauer S., Brunner R., Lechner K., and Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 3 (1997) 1419-1425
22. Leith C.P., Kopecky K.J., Chen I.M., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
23. van der Kolk D.M., Vellenga E., Scheffer G.L., et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99 (2002) 3763-3770
24. van der Pol M.A., Broxterman H.J., Pater J.M., et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88 (2003) 134-147
25. Beck W.T., Grogan T.M., Willman C.L., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56 (1996) 3010-3020
26. Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11 (2001) 1156-1166
27. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
28. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
29. Greenwood M.J., Seftel M.D., Richardson C., et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 47 (2006) 1245-1252
30. Abolhoda A., Wilson A.E., Ross H., Danenberg P.V., Burt M., and Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5 (1999) 3352-3356
31. Lyttelton M.P., Hart S., Ganeshaguru K., Hoffbrand A.V., and Mehta A.B. Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non-isotopic quantitative cDNA-polymerase chain reaction. Br J Haematol 86 (1994) 540-546
32. Wood P., Burgess R., MacGregor A., and Yin J.A. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 87 (1994) 509-514
33. Zhou D.C., Zittoun R., and Marie J.P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9 (1995) 1661-1666
34. Blair A., Hogge D.E., and Sutherland H.J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 92 (1998) 4325-4335
35. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
36. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
37. Ailles L.E., Gerhard B., Kawagoe H., and Hogge D.E. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94 (1999) 1761-1772
38. Johny A., Song K.W., Nantel S.H., et al. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biol Blood Marrow Transplant 12 (2006) 480-489
39. Bradley G., Naik M., and Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 49 (1989) 2790-2796
40. Efferth T., Davey M., Olbrich A., Rucker G., Gebhart E., and Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28 (2002) 160-168
41. Kawagoe H., Humphries R.K., Blair A., Sutherland H.J., and Hogge D.E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13 (1999) 687-698
42. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
43. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
44. Guan Y., Gerhard B., and Hogge D.E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101 (2003) 3142-3149
45. Cros E., Jordheim L., Dumontet C., and Galmarini C.M. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 45 (2004) 1123-1132
46. Chaudhary P.M., and Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66 (1991) 85-94
47. Scharenberg C.W., Harkey M.A., and Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99 (2002) 507-512
48. de Grouw E.P., Raaijmakers M.H., Boezeman J.B., et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 20 (2006) 750-754
49. List A.F., Kopecky K.J., Willman C.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220